Original Research

DOI: 10.4244/EIJ-D-23-00720

One-year clinical outcomes of transcatheter aortic valve implantation with the latest iteration of self-expanding or balloon expandable devices: insights from the OPERA-TAVI registry

Giuliano Costa1, MD; Francesco Saia2, MD; Thomas Pilgrim3, MD; Mohamed Abdel-Wahab4, MD; Philippe Garot5, MD; Sofia Sammartino1, MD; Caterina Gandolfo6, MD; Luca Branca7, MD; Azeem Latib8, MD; Ignacio Amat-Santos9, MD; Darren Mylotte10, MD; Federico De Marco11, MD; Ole De Backer12, MD; Luis Nombela Franco13, MD; Mariama Akodad5,14, MD, PhD; Flavio Luciano Ribichini15, MD; Francesco Bedogni16, MD; Alessandro Mazzapicchi2, MD; Daijiro Tomii3, MD; Pietro Laforgia5, MD; Stefano Cannata6, MD; Claudia Fiorina7, MD; Andrea Scotti8, MD; Simone Fezzi10, MD; Enrico Criscione16, MD; Enrico Poletti16, MD; Mattia Mazzucca16, MD; Mattia Lunardi15, MD; Andrea Mainardi15, MD; Stefano Andreaggi15, MD; Angelo Quagliana12, MD; Nicholas J. Montarello12, MD; Breda Hennessey13, MD; Matias Mon-Noboa13, MD; David Meier14, MD; Marianna Adamo7, MD; Carmelo Sgroi1, MD; Claudia Maria Reddavid1, MD; Orazio Strazzieri1, MD; Silvia Crescenzia Motta1, MD; Valentina Frittitta1, MD; Elena Dipietro1, MD; Alessandro Comis1, MD; Chiara Melfa1, MD; Mariachiara Calì1, MD; Giulia Laterra17, MD; Holger Thiele4, MD; John G. Webb14, MD; Lars Sondergaard12,18, MD; Corrado Tamburino1, MD; Marco Barbanti19, MD

Abstract

Background: Midterm comparative analyses of the latest iterations of the most used Evolut and SAPIEN platforms for transcatheter aortic valve implantation (TAVI) are lacking.

Aims: We aimed to compare 1-year clinical outcomes of TAVI patients receiving Evolut PRO/PRO+ (PRO) or SAPIEN 3 Ultra (ULTRA) devices in current real-world practice.

Methods: Among patients enrolled in the OPERA-TAVI registry, patients with complete 1-year follow-up were considered for the purpose of this analysis. One-to-one propensity score matching was used to compare TAVI patients receiving PRO or ULTRA devices. The primary endpoint was a composite of 1-year all-cause death, disabling stroke and rehospitalisation for heart failure. Five prespecified subgroups of patients were considered according to leaflet and left ventricular outflow tract calcifications, annulus dimensions and angulation, and leaflet morphology.

Results: Among a total of 1,897 patients, 587 matched pairs of patients with similar clinical and anatomical characteristics were compared. The primary composite endpoint did not differ between patients receiving PRO or ULTRA devices (Kaplan-Meier [KM] estimates 14.0% vs 11.9%; log-rank p=0.27). Patients receiving PRO devices had higher rates of 1-year disabling stroke (KM estimates 2.6% vs 0.4%; log-rank p=0.001), predominantly occurring within 30 days after TAVI (1.4% vs 0.0%; p=0.004). Outcomes were consistent across all the prespecified subsets of anatomical scenarios (all pinteraction>0.10).

Conclusions: One-year clinical outcomes of patients undergoing transfemoral TAVI and receiving PRO or ULTRA devices in the current clinical practice were similar, but PRO patients had higher rates of disabling stroke. Outcomes did not differ across the different anatomical subsets of the aortic root.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 1
Jan 1, 2024
Volume 20 Number 1
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-22-00050 Jan 23, 2023
Rocky II, Rambo II, and the ACURATE neo2
Serruys PW et al
free

Clinical research

10.4244/EIJ-D-22-00164 Jan 23, 2023
ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation
Pellegrini C et al
free

Clinical research

10.4244/EIJ-D-22-00498 Jan 23, 2023
Comparison of transcatheter aortic valve replacement with the ACURATE neo2 versus Evolut PRO/PRO+ devices
Baggio S et al
free

Editorial

10.4244/EIJ-E-23-00009 Apr 24, 2023
SAPIEN 3 Ultra: better sealing, reduced paravalvular leak and a move in the right direction?
Reardon MJ and Goel SS
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved